Paliperidone, risperidone, and olanzapine depot injection Special Authority approvals
Thank you for your request dated 21 December 2021 under the Official Information Act 1982 (OIA) for information relating to Special Authority approvals for antipsychotic depot injections paliperidone, risperidone, and olanzapine. You requested:
The numbers of Special Authority Initiations and Renewals for 2018, 2019 & 2020 by DHB for the following products:
- SA1429 Invega Sustenna (paliperidone palmitate depot injection)
- SA1427 Risperdal Consta (risperidone microspheres)
- SA1428 Zyprexa Relprevv (olanzapine pamoate monohydrate depot injection)
Please note, where fewer than 10 applications are approved, we have changed the number to "<10" as we believe this is necessary to protect the privacy of these people (section 9(2)(a) of the OIA). This is because we approach our assessment of requests for information under the OIA on the basis that once we release the information to you, it becomes available to any other party in that exact form (whether by you distributing it to others or by virtue of us receiving the same request from a different third party).
As required under the OIA, we also considered whether, in the circumstances, the withholding of this information was outweighed by other considerations which render it desirable, in the public interest, to make this information available. In this case we did not consider that the public interest outweighed the reasons for withholding the information.
Please note you have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision.
We trust that this information answers your queries. We are making our information more freely available, so we now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.